“Insiders Buying Pfizer Stock at a 52 Week Low! | Pfizer (PFE) Stock Analysis! |”
PFE is not a good buy now; dividend sustainability is questionable as payouts exceed FCF, and DCF analysis suggests significant downside despite insider buys.
A high-yield dividend stock just saw insiders start buying for the first time in over a year and a half, and I'm not going to make you wait to reveal the stock. It's Pfizer.
And Pfizer is a stock that's really struggled over the last few years. I've been covering it for a while now, but it's yielding around 6.4% at its current prices. However, I've pointed out some major concerns I have with the company at least over the last few years, and you can see the share price has been decimated.
If we look in the last 5 years, the stock is down by 41 nearly 42% in the last 6 months alone, down by 2.61%.